Lipoprotein(a) [Lp(a)]

Definition

Lipoprotein(a) is an LDL-like particle with a single apolipoprotein(a) [apo(a)] strand covalently bound to its ApoB-100 component. Unlike LDL, Lp(a) levels are predominantly genetically determined (~80–90% heritability) via the LPA gene, remain stable across the lifespan, and are only minimally modified by lifestyle. Lp(a) is a causal risk factor for ASCVD and calcific aortic valve disease, with risk increasing continuously at higher concentrations across all ancestries.

Key Concepts

Structure and Assembly

• Lp(a) = LDL-like lipid core + apoB100 + apolipoprotein(a) [apo(a)] linked via a single disulfide bond sources/lpa-aha-2021 (very high)
• Apo(a) contains 10 kringle IV (KIV) subtypes; KIV type 2 is present in variable copy numbers → highly variable molecular mass (300–800 kDa); carries covalently bound oxidised phospholipids (OxPLs) on KIV type 10
• Assembly: 2-step process — (1) noncovalent lysine-dependent interaction between apo(a) KIV and the N-terminal domain of apoB, followed by (2) extracellular covalent disulfide bond formation sources/lpa-aha-2021 (very high)
• LPA gene evolved by duplication of the plasminogen (PLG) gene — explains structural homology and proposed antifibrinolytic properties; species distribution limited to humans, Old World monkeys, apes, and hedgehogs (limits animal model research) sources/lpa-aha-2021 (very high)
• Liver is the primary site of Lp(a) catabolism; clearance receptors not definitively identified (LDL-R, SR-B1, LRP1, LRP8 implicated) sources/lpa-aha-2021 (very high)

Epidemiology and Genetics

• Population distribution is highly skewed, highest levels in individuals of African or South Asian ancestry sources/lipid-aha-2026 (very high)
• Mean/median Lp(a) approximately 7–20 mg/dL (20 nmol/L) in general population; ~20% of population has levels ≥50 mg/dL (125 nmol/L) = "elevated"
• Inherited with autosomal codominant transmission; genetic testing for LPA not advised for clinical purposes — measured Lp(a) concentration is sufficient
• Lp(a) concentration determined by number of kringle IV-type 2 (KIV-2) repeats in apo(a); inverse relationship — more repeats → smaller isoform → lower Lp(a) in most assays (mass-based)
• KIV2 copy number variant accounts for 19–69% of interindividual heterogeneity; additional LPA SNPs explain further variation sources/lpa-aha-2021 (very high)
• APOE ε2 allele associated with lower Lp(a) levels (~0.5% of variation); APOH (β2-glycoprotein 1, which binds apo(a) KIV2) also implicated sources/lpa-aha-2021 (very high)
• Intraindividual biological variability up to 20% — consider averaging 2 measurements for borderline-risk individuals before making treatment decisions sources/lpa-aha-2021 (very high)

Risk Quantification

• Prospective studies show robust associations with nonfatal ASCVD, aortic valve disease, CVD, and all-cause mortality sources/lipid-aha-2026 (very high)
• Risk is independent of LDL-C and other risk factors, even at low LDL-C
• Relative risk compared with population median (~7 mg/dL / 20 nmol/L):

• Risk derived from UK Biobank (Patel et al, n=460,000); HR 1.11 per 50 nmol/L increment (95% CI 1.10–1.12), log-linear above median, similar across ancestry groups sources/lpa-aha-2021 (very high)
• Practical risk-adjustment formula (validated with PCE framework, predates PREVENT):
  Updated 10-y risk = PCE risk × 1.11^(Lp(a) nmol/L ÷ 50)
  Example: PCE 10% + Lp(a) 250 nmol/L → 10% × 1.11^5 = 16.9% sources/lpa-aha-2021 (very high)
• Stroke: causal role for Lp(a) weaker than for CHD/CAVD; Mendelian randomization data show ~13% lower stroke risk per 1 SD lower genetically determined Lp(a) vs ~30–40% lower risk for CHD/PAD/CAVD sources/lpa-aha-2021 (very high)
• Venous thromboembolism: genetic data do not support a meaningful VTE–Lp(a) association except at very high levels; apo(a) antifibrinolytic properties in vitro likely masked when covalently bound to apoB in the Lp(a) particle sources/lpa-aha-2021 (very high)
• Relative risk from Lp(a) is multiplicative with other cardiovascular risk factors — elevated Lp(a) + additional risk factors = compounded risk

Measurement and Assay Standardisation

• Historical dual-unit problem: Lp(a) has long been measured in two incompatible units — mg/dL (total Lp(a) mass, assumes constant component proportions — scientifically invalid given apo(a) size variability) and nmol/L (molar concentration of apo(a) particles — preferred, isoform-insensitive) sources/lpa-aha-2021 (very high)
• Gold-standard assay: isoform-insensitive ELISA calibrated in nmol/L, traceable to WHO/IFCC Reference Material SRM-2B; multiple guidelines now mandate nmol/L reporting sources/lpa-aha-2021 (very high)
• No unbiased conversion factor from mg/dL to nmol/L — do not convert between units; results from differently calibrated assays are not directly comparable
• A mass spectrometry candidate reference method has been validated with high concordance to the gold-standard ELISA sources/lpa-aha-2021 (very high)
• COR 1: Measure at least once in all adults for ASCVD risk assessment sources/lipid-aha-2026 (very high)
• COR 1: Cascade testing of first-degree family members if FH, premature ASCVD, or high Lp(a)
• COR 1: Use assays insensitive to apo(a) isoform size and traceable to official reference standard materials
• Reported in either nmol/L (molar) or mg/dL (mass); molar units preferred — isoform-insensitive
• Fasting NOT required for Lp(a) testing
• Single measurement generally sufficient; stable except in menopause transition, kidney/liver/thyroid disease, pregnancy, or certain medications
• Secondary causes of elevated Lp(a): kidney disease, liver disease, thyroid disease, pregnancy, menopause, some medications (inflammation may increase or decrease)

Clinical Significance as Risk Enhancer

• Lp(a) ≥125 nmol/L (50 mg/dL) classified as a risk enhancer in primary prevention sources/lipid-aha-2026 (very high)
• Should trigger more intensive management of all modifiable cardiovascular risk factors
• At ≥430 nmol/L: risk equivalent to HeFH — warrants very aggressive ASCVD risk reduction
• Lp(a) is additive to LDL-C, hsCRP, and conventional risk factors; in Women's Health Study, 20-year HR for MACE: hsCRP top quintile 1.70, LDL-C top quintile 1.35, Lp(a) top quintile 1.33

Management of Elevated Lp(a)

Step 1 — Optimize modifiable risk factors (COR 1):

• Intensive control of LDL-C, blood pressure, glycaemia
• Smoking cessation, healthful diet, physical activity (AHA Life's Essential 8)
• Observational data: lifestyle alignment associated with 67% lower ASCVD risk among those with elevated Lp(a) sources/lipid-aha-2026 (very high)

Step 2 — Intensify LDL-C lowering:

• Statins: do NOT lower Lp(a); may modestly increase by mean ~1.1 mg/dL (not clinically significant; does not justify statin discontinuation)
• High-intensity statin: still provides ~30–40% RRR in events among those with elevated Lp(a) (JUPITER trial: on-treatment LDL-C 54 mg/dL)

Step 3 — Add PCSK9 inhibitor (for ASCVD + elevated Lp(a)):

• In ASCVD + elevated Lp(a) not at LDL-C/non-HDL-C goals on max statin → add PCSK9 mAb (COR 1) sources/lipid-aha-2026 (very high)
• PCSK9 mAbs (evolocumab, alirocumab) lower Lp(a) by ~15–30% (not FDA-approved specifically for Lp(a))
• Post hoc FOURIER and prespecified ODYSSEY Outcomes analyses: patients with higher Lp(a) derive greater benefit; Lp(a) lowering may have contributed to event reduction
• Alirocumab ODYSSEY pooled analysis: Lp(a) reduction only associated with CV event reduction in those with Lp(a) ≥50 mg/dL

Emerging therapies (investigational):

• mRNA-targeting therapies (antisense oligonucleotides, siRNA): dramatically lower Lp(a) by >80%; currently in phase 3 cardiovascular outcomes trials
• Oral small-molecule inhibitors of Lp(a) production also in development
• Lipoprotein apheresis: FDA-approved for Lp(a) ≥60 mg/dL + FH + CAD/PAD (observational basis only)
• Aspirin: post hoc analyses in 2 primary prevention trials showed reduced events in high Lp(a) — prospective trials needed

ESC 2025: Lp(a) as CV Risk-Enhancing Factor

• COR IIa B (new ESC 2025 recommendation): Lp(a) levels above 50 mg/dL (105 nmol/L) should be considered in all adults as a CV risk-enhancing factor, with higher Lp(a) levels associated with greater increase in risk sources/lipid-esc-2025 (very high)
• ESC 2025 threshold for risk modifier: >50 mg/dL (>105 nmol/L) — defined as affecting at least 20% of the population
• ESC 2025 specifically designates Lp(a) >105 nmol/L as a risk modifier to potentially reclassify moderate-risk individuals or those around treatment decision thresholds to higher category (Box 1)
• ESC 2025 confirms statins have no effect on Lp(a) concentrations (individual-level data from 7 placebo-controlled statin trials); clinical decision-making should not be affected by this — patients with high Lp(a) should still take high-intensity statins if risk is sufficiently high
• ESC 2025 on emerging RNA therapies: ASO/siRNA targeting apo(a) production → 80–98% Lp(a) reduction; oral small-molecule inhibitors also in development; phase 3 CVOTs ongoing

Contradictions / Open Questions

• No dedicated cardiovascular outcomes trial has shown that specifically lowering Lp(a) reduces ASCVD events — all existing data are post hoc or from mechanistic studies; phase 3 RCTs with Lp(a)-specific agents (olpasiran, pelacarsen, zerlasiran) are ongoing
• Optimal Lp(a) treatment threshold remains uncertain: current COR 1 recommendation to lower LDL-C more if ASCVD + elevated Lp(a), but whether specific Lp(a)-lowering is warranted at 125–249 nmol/L vs ≥250 nmol/L vs ≥430 nmol/L is unclear
• Interassay variability: nmol/L-to-mg/dL conversion is approximate (~2.5×); comparison of results between laboratories remains unreliable without standardization
• ESC vs ACC/AHA Lp(a) threshold discrepancy: ESC 2025 designates Lp(a) >50 mg/dL (>105 nmol/L) as risk-enhancing; ACC/AHA 2026 uses ≥125 nmol/L (≥50 mg/dL) as risk enhancer — the same mass threshold but the molar threshold differs (ESC 105 nmol/L vs ACC/AHA 125 nmol/L). The discrepancy (~20 nmol/L) arises from differences in reference populations and conversion approximations. This means patients with Lp(a) 105–124 nmol/L are considered elevated by ESC but not yet by ACC/AHA sources/lipid-esc-2025 sources/lipid-aha-2026 (both very high)

Lp(a) in Calcific Aortic Valve Disease (CAVD)

• Lp(a) has an independent causal role in CAVD initiation (Mendelian randomization), distinct from and additive to LDL-C sources/vhd-mechanism-aha-2024 (very high)
• Mechanism: covalently linked oxidised phospholipids on Lp(a) → activate osteogenic transcriptional programs in valve interstitial cells (VICs) → fibrocalcific transformation
• Autotaxin (ATX): enzyme metabolising Lp(a)-associated lysophosphatidylcholine; ATX gene expression elevated in CAVD VICs; associated with circulating Lp(a); autotaxin overexpression promotes valve mineralisation in murine models sources/vhd-mechanism-aha-2024 (very high)
• Lp(a) is associated with CAVD onset but NOT with progression of established aortic valve calcification — important therapeutic window implication; early Lp(a) lowering may be necessary before calcification is established
• Pelacarsen (anti-sense oligonucleotide targeting LPA): active phase 2/3 trial targeting AS progression (NCT05646381, n=502); primary endpoints — aortic valve calcium score + peak AV velocity; will be first RCT to test Lp(a)-specific lowering in AS sources/vhd-mechanism-aha-2024 (very high)
• See concepts/CAVD-Mechanisms for full CAVD molecular pathway

Connections

• Related to concepts/Dyslipidemia-Management — Lp(a) measurement and management are integrated into the overall lipid guideline
• Related to concepts/ASCVD-Risk-Assessment — Lp(a) ≥125 nmol/L is a key risk enhancer in CPR Framework
• Related to concepts/Familial-Hypercholesterolemia — elevated Lp(a) is common in FH (ascertainment bias); doubles risk on top of FH
• Related to concepts/CAVD-Mechanisms — Lp(a) as causal driver of CAVD initiation via oxidised phospholipids and autotaxin

Sources

• sources/lipid-aha-2026
• sources/lipid-esc-2025
• sources/lpa-aha-2021
• sources/vhd-mechanism-aha-2024